Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response

Schauer, Dominic; Starlinger, Patrick; Alidzanovic, Lejla; Zajc, Philipp; Maier, Τ.; Feldman, Alexandra; Padickakudy, R.; Buchberger, Elisabeth; Elleder,; Spittler, Andreas; Stift, Judith; L, Pop; Gruenberger, Birgit; Gruenberger, Thomas; Brostjan, Christine

doi:10.1080/2162402x.2016.1160185

Cited by 14 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, it was shown that chemotherapy associated elevations in blood monocytes confers a survival advantage (19). However, we propose that increases in monocytes with higher infiltration of M1 macrophages during/after chemotherapy can elicit robust anti-tumor responses.…”

Section: Q213 Amplified Tumors Show Differential Immune Cell Enrichmentioning

confidence: 66%

1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

Venkata

Ghersi²,

Ganti³

et al. 2020

Preprint

View full text Add to dashboard Cite

The contrast in therapy sensitivity and response across triple negative breast cancer (TNBC) patients suggest underlying genotypic heterogeneity. Using publicly available data, we found significant associations between DNA-level copy number alterations of 1q21.3 locus and therapy sensitivity. We show that in spite of their aggressive nature, 1q21.3 amplified tumors are more responsive to commonly used cytotoxic therapies, highlighting the relevance of 1q21.3 copy number status as a genetic marker for risk stratification, therapy selection and response.

show abstract

Section: Q213 Amplified Tumors Show Differential Immune Cell Enrichmentioning

confidence: 66%

1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

Venkata

Ghersi²,

Ganti³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Accordingly, there is a need for more sensitive, specific, and reliable haematological parameters to monitor therapeutic response to such treatment. In particular, allowing for tumor sufferers receiving translational treatment, an easy and rapid approach to evaluate antitumor efficacy after only 4 weeks (two cycles) would make allowance for a timely conversion in clinical regimens to accomplish resection of hepatic metastases and minimize hepatic toxicity of successive therapy schedules [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients

Jie-zhen

2017

Oncotarget

View full text Add to dashboard Cite

PurposeThe evaluation of regulatory T (Treg) (CD4+CD25high CD127neg) lymphocyte count with respect to the T helper (TH) (CD4) number has been shown to represent the main immune parameters capable of signifying the functional status of the anticancer immunity in cancer patients. This study is aimed to explore a correlation between therapy efficacy and changes in Treg/TH ratio and other biochemical and haematological parameters in patients with metastatic colorectal cancer (mCRC).Experimental DesignMeasurements of regulatory T cells were performed by flow cytometric analysis pre- and post-therapies in a prospective study.ResultsWe investigated levels of Treg/TH ratio in the peripheral blood of 25 mCRC patients pre- and post-chemotherapy ± targeted therapy. There were significant differences in levels of Treg/TH ratio pre- and post-treatments among patients on study, patients with partial response (PR), stable disease (SD) and progressive disease (PD) (P= 0.012, P= 0.011, and P= 0.043, respectively). Moreover, the relative change in Treg/TH ratio showed statistically significant difference among patients with PD as compared to those with PR and SD. Our findings demonstrated a statistically significant strong correlation between the relative change in Treg/TH ratio and therapeutic response. (Spearman's rho= 0.788/p<0.001).ConclusionsThe monitoring of the relative change in Treg/TH ratio could constitute a promising clinical index for response prediction and a timely change in regimen. Further prospective evaluations of these parameters investigated, particularly their association with overall survival, are warranted.

show abstract

“…TEM frequency in the peripheral blood of CRC patients and healthy individuals did not differ significantly 49,50 but the levels of TIE-2 expression at the surface of CD14 + cells were significantly higher in patients relative to healthy individuals 49 . More recently, the low levels of circulating TEM in CRC were confirmed, even after the addition of anti-VEGF to standard chemotherapy 51 . Finally, in CRC, TEM frequencies and levels of TIE-2 expression did not correlate with tumor microvessel density, tumor stage, or pathological and clinical end points in CRC patients 49 …”

Section: Other Solid Tumor Typesmentioning

confidence: 98%

TIE-2 expressing monocytes in human cancers

et al. 2017

View full text Add to dashboard Cite

Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with proangiogenic activity. TIE-2 expressing monocytes (TEM) were found both in humans and mice. Here, we review the phenotypes and functions of TEM reported so far in human cancer and their potential use as markers of cancer progression and metastasis. Finally, we discuss the therapeutic approaches currently used or proposed to target TEM.

show abstract

Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response

Cited by 14 publications

References 29 publications

1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients

TIE-2 expressing monocytes in human cancers

Contact Info

Product

Resources

About